A PROSPECTIVE COHORT STUDY FOR COMPREHENSIVE ASSESSMENT OF RESPIRATORY MORBIDITY OF COVID-19 AMONG SARS-COV2 SURVIVORS
Main Article Content
Keywords
SARS-CoV-2, Covid-19, Lung
Abstract
Introduction: COVID-19, caused by the novel coronavirus SARS-CoV-2, was first identified in December 2019 in Wuhan, China. It rapidly evolved into a global health crisis, challenging modern healthcare systems and public health policies. Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), refers to a range of symptoms and health complications that persist for weeks or months after the acute phase of COVID-19 has resolved. The World Health Organization (WHO) defines Long COVID as symptoms that last for at least two months and occur three months after infection. These symptoms can significantly impact the quality of life, with some patients experiencing lasting issues long after recovery from the initial infection. This study was done with the aim to investigate the impact of extended morbidity of covid-19 among SARS CoV-2 survivors.
Material and method: The study is conducted at the Department of Respiratory Medicine, National Institute of Medical Science and Research, Jaipur, Rajasthan. We observed 235 patients in 18 months period.
Result: A total of 235 participants were included in this prospective cohort study assessing respiratory morbidity among SARS-CoV-2 survivors. Of the study population, 136 (57.9%) were male, and 99 (42.1%) were female. The mean age of the participants was 59.49 years, with a standard deviation of ±16.99 years
Conclusion: Given the complexity of the long-term impact of COVID-19, further research is critical to fully understand the mechanisms behind these lingering symptoms and immune responses. Longitudinal studies exploring immune system regulation, including the role of IgG and other immune markers, in SARS-CoV-2 survivors are necessary to identify potential therapeutic targets. Moreover, a deeper understanding of how severe illness and comorbidities influence long-term respiratory
health is essential to developing strategies for better management and recovery of affected individuals. Ultimately, such research will contribute to improving clinical management strategies and enhancing quality of life for COVID-19 survivor.
References
2. Jentsch, P. C., Anand, M., Bauch, C. T. (2021). Prioritising COVID-19 vaccination in changing social and epidemiological landscapes. The Lancet Infectious Diseases, 21(8), 1097–1106.
3. Cornberg, M., Buti, M., Eberhardt, C. S., et al. (2021). EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases. Journal of Hepatology, 74(4), 944–951.
4. Chen, N., Zhou, M., Dong, X., et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China. The Lancet, 395(10223), 507-513.
5. Pascual-Figal DA, Roura-Piloto AE, Moral-Escudero E, Bernal E, Albendin-Iglesias H, Pérez-Martínez MT, Noguera-Velasco JA, Cebreiros-Lopez I, Hernandez-Vicente A, Vazquez-Andres D, Sanchez-Perez C. Colchicine in recently hospitalized patients with COVID-19: a randomized controlled trial (COL-COVID). International Journal of General Medicine. 2021 Sep 11:5517-26.https://www.who.int/emergencies/diseases/novel-coronavirus-2019
6. Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID- 19. JAMA. 2020;324(6):603-605.
7. Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618.
8. Cotti C, Arora S, Goyal A. Gastrointestinal symptoms in COVID-19: A systematic review and meta-analysis. Am J Gastroenterol. 2020;115(3):562-572.
9. Zhang Y, Li H, Li M, et al. Clinical characteristics and the risk factors for mortality of COVID-19 patients: A meta-analysis. J Clin Med. 2021;10(6):1254.
10. Yan Z, Yang M, Lai CL, et al. Prevalence of post-acute COVID-19 syndrome in patients with different severities of COVID-19: A systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):573.
11. Liu Y, Bi L, Chen X, et al. Pulmonary rehabilitation in post-COVID-19 patients: A review. Front Med. 2021;8:668.
12. Bellan M, Soddu D, Balbo PE, et al. Respiratory and cognitive sequelae of Covid-19: A longitudinal observational study. J Infect. 2021;82(1):e30-e31.
13. Bechter K, Müller MP. Long COVID and persistent symptoms after SARS-CoV-2 infection: Pathophysiology, diagnosis, and therapy. Klin Wochenschr. 2021;99(7):349- 359.
14. Ponsford M, Cronin C, Padykula A. Persistent immune dysfunction in COVID-19 survivors: Evidence from a cohort study. Immunology. 2021;164(3):440-449.
15. Koidou I, Tsakiridis K, Kountouri A, et al. Elevated serum IgG levels in severe COVID- 19 patients. J Allergy Clin Immunol. 2021;147(1): 203-204.
16. Akhavan P, Ghaffari J, Rahmanian S, et al. Radiological findings in COVID-19 survivors. J Med Imaging Radiat Sci. 2021;52(4):628-634.
17. Lee YJ, Lee AR, Lee HJ, et al. Long-term pulmonary sequelae in COVID-19 survivors: Radiological and clinical outcomes. J Thorac Imaging. 2021;36(5):271-276.
18. Wang W, Jiang X, Zhang Y, et al. Radiological findings in COVID-19 survivors: A systematic review and meta-analysis. Clin Imaging. 2021;75:42-50.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Nisha Kaushik
Postgraduate student, Department of Respiratory Medicine, NIMS University, Jaipur
Dr. Nalin Joshi
Professor, Department of Respiratory Medicine, NIMS University, Jaipur
Dr. Pradeep Soothwal
Associate Professor, Department of Respiratory Medicine, NIMS University, Jaipur
Dr. R.C. Meena
Professor, Department of Respiratory Medicine, NIMS University, Jaipur